Impact of Utilizing a Composite versus a Symptom-Only Validation Standard in the Development of the Asthma Impairment and Risk Questionnaire
J Asthma Allergy
.
2024 Aug 7:17:751-756.
doi: 10.2147/JAA.S461524.
eCollection 2024.
Authors
Bradley E Chipps
1
,
Robert S Zeiger
2
,
David A Beuther
3
,
Robert A Wise
4
,
William McCann
5
,
Joan Reibman
6
,
Maureen George
7
,
Ileen Gilbert
8
,
James M Eudicone
8
,
Karin S Coyne
9
,
Gale Harding
9
,
Kevin R Murphy
10
Affiliations
1
Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA.
2
Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
3
Department of Medicine, National Jewish Health, Denver, CO, USA.
4
Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
5
Allergy Partners, Asheville, NC, USA.
6
Department of Medicine, New York University School of Medicine, New York, NY, USA.
7
Columbia University School of Nursing, New York, NY, USA.
8
BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
9
Evidera, Bethesda, MD, USA.
10
Boys Town National Research Hospital, Boys Town, NE, USA.
PMID:
39131600
PMCID:
PMC11317051
DOI:
10.2147/JAA.S461524
No abstract available
Grants and funding
This study was supported by AstraZeneca (Wilmington, DE, USA). The Asthma Impairment and Risk Questionnaire (AIRQ) was developed with support from the AstraZeneca PRECISION program.